Filing summary
Entity and period: The supplied filing is PerkinElmer, Inc.’s unaudited Form 10-Q for the fiscal quarter ended October 3, 2010, not a filing identified as Revvity, Inc. The filing reports fiscal 2010’s third quarter and first nine months, compared with the periods ended October 4, 2009.
Financial performance
| Metric | Q3 2010 | Q3 2009 | Nine months 2010 | Nine months 2009 |
|---|---|---|---|---|
| Continuing-operations sales | $419.1 million | $377.0 million | $1,234.4 million | $1,122.3 million |
| Operating income, continuing operations | $41.4 million | $21.9 million | $105.3 million | $72.3 million |
| Continuing-operations net income | $26.5 million | $13.3 million | $93.4 million | $41.4 million |
| Net income, including discontinued operations | $13.4 million | $13.6 million | $95.4 million | $45.7 million |
| Continuing-operations operating margin | 9.9% | 5.8% | 8.5% | 6.4% |
| Gross margin | 44.3% | 44.8% | 44.6% | 45.0% |
- Quarterly sales rose 11%; nine-month sales rose 10%. Management cited recovering end markets, higher sales volume, acquisitions and growth in laboratory services, environmental/safety products and diagnostics.
- Q3 segment sales and operating income: Human Health $194.5 million and $25.0 million; Environmental Health $224.6 million and $26.1 million. Environmental Health operating income increased 132% year over year; Human Health increased 31%.
- Gross margin declined about 40 basis points in both comparison periods, primarily from product mix, partly offset by productivity and cost controls. Operating margin improved on higher volume and cost containment.
- Q3 net income was nearly flat despite higher continuing-operations income, principally because discontinued operations recorded a $12.9 million after-tax loss. This included $17.1 million of tax expense when foreign earnings of subsidiaries classified as held for sale no longer qualified for permanent-reinvestment treatment.
- Nine-month continuing-operations income included a $25.6 million pretax gain from remeasuring the previously held interest in the ICPMS joint venture. The filing also reports $4.2 million of continuing-operations tax benefits from tax-position remeasurements and audit resolutions.
Cash flow, liquidity and debt
- For the first nine months, operating cash flow was $120.9 million from continuing operations and $135.3 million including discontinued operations. Continuing-operations investing cash outflow was $162.1 million, including acquisition-related spending; financing cash inflow was $92.4 million. Cash increased $71.3 million to $251.0 million.
- Capital expenditures were $22.9 million. The company paid $24.7 million in dividends and made a voluntary $30.0 million U.S. pension contribution.
- At October 3, cash was $251.0 million; short-term debt was $0.2 million and long-term debt was $670.1 million. The $650 million revolving facility had $518 million drawn; approximately $118 million remained available after letters of credit.
- Revolver borrowings carried a 0.66% effective Eurocurrency rate at quarter-end; the company also had $150 million of 6% senior notes due in May 2015. Management reported covenant compliance and expected continued compliance.
- Current assets were $977.6 million and current liabilities were $513.8 million, including amounts related to discontinued operations. Inventory rose to $210.2 million from $178.7 million at fiscal year-end.
Material developments, outlook and risks
- PerkinElmer agreed to sell its Illumination and Detection Solutions business for approximately $500 million, or $482 million net of acquired cash, subject to working-capital adjustments and customary closing conditions. Closing was expected by fiscal year-end 2010; management expected a gain and intended to reinvest proceeds in its remaining markets. The transaction had not closed as of the reporting date.
- 2010 acquisitions included Signature Genomic Laboratories ($90 million cash consideration), VisEn Medical ($23 million) and the remaining interest in the ICPMS joint venture ($35 million cash consideration, plus other consideration). Purchase-price allocations, including VisEn’s, remained subject to estimates and adjustment.
- Management described recovery across many markets, while noting continuing tight pharmaceutical and public-lab budgets, lower U.S. birth rates affecting neonatal screening, and product-mix pressure. It provided no specific revenue or earnings guidance in the supplied text.
- Restructuring charges were $9.8 million for the first nine months. The Q2 2010 plan reduced headcount by 115; remaining severance and facility obligations were expected to be paid over periods extending as far as fiscal 2022.
- Key risks include economic and customer-funding weakness, foreign exchange, variable-rate debt and credit availability, acquisition integration and divestiture execution, regulation, intellectual-property disputes, and possible impairment of substantial goodwill and intangible assets. Environmental remediation accruals were $6.2 million. The Enzo patent case remained stayed; management said it did not expect a material adverse financial effect, while acknowledging uncertainty.
- Management stated that disclosure controls were effective and that no material change in internal control over financial reporting occurred during the quarter.
Investor verification priorities
- Confirm the filing identity: the source names PerkinElmer, Inc., while the request names Revvity, Inc.; verify the intended issuer and historical corporate relationship.
- Check the subsequent closing, final proceeds, working-capital adjustment and recognized gain on the IDS sale.
- Separate ongoing performance from discontinued operations and one-time items, especially the held-for-sale tax charge and ICPMS remeasurement gain.
- Review debt availability, covenant headroom, variable-rate exposure and cash needs for acquisitions, pension funding and restructuring.
- Assess whether acquisition integration, goodwill valuations, tax uncertainties and disclosed legal or environmental contingencies changed after the reporting date.